Munich

The trials here

What the 15 trials at this site are about, from their registry records.

Conditions

• Coronary artery disease3 trials
• Familial hypercholesterolaemia3 trials
• Multiple sclerosis3 trials
• Stroke2 trials
• Chronic myeloid leukaemia1 trial
• Diabetic eye disease1 trial
• Hidradenitis suppurativa1 trial
• Idiopathic pulmonary fibrosis1 trial
• Macular degeneration1 trial
• Metastatic breast cancer1 trial
• Peripheral artery disease1 trial
• Prostate cancer1 trial

Phase

• Phase 37 trials
• Phase 21 trial
• Phase 41 trial

Status

• Completed7 trials
• Recruiting4 trials
• Active, not recruiting2 trials
• Terminated1 trial
• Withdrawn1 trial

Lead sponsor

• Novartis Pharmaceuticals15 trials

Running trials

• Recruiting

  A Study to Evaluate the Efficacy of NIO752 in Participants With Progressive Supranuclear Palsy

  NCT07498426· Phase 3· Novartis Pharmaceuticals· Source

  Contact: Novartis Pharmaceuticals

• Active, not recruiting

  An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)

  NCT07517263· Phase 3· Novartis Pharmaceuticals· Source

• Recruiting

  A Study on the Tolerability, Safety and Effectiveness of Asciminib in Patients With Philadelphia Chromosome-positive Chronic Myeloid Leukemia in the Chronic Phase in Germany

  NCT07549516· Novartis Pharmaceuticals· Source

  Contact: Novartis Pharmaceuticals

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis

  NCT07225504· Phase 3· Novartis Pharmaceuticals· Source

  Contact: Novartis Pharmaceuticals

• Recruiting

  Real-world Experience With Lutetium Vipivotide Tetraxetan in Metastatic Castration Resistant Prostate Cancer

  NCT06517719· Novartis Pharmaceuticals· Source

  Contact: Novartis Pharmaceuticals

• Active, not recruiting

  Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS

  NCT03650114· Phase 3· Novartis Pharmaceuticals· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Chronic myeloid leukaemia1 recruiting
• Multiple sclerosis1 recruiting
• Prostate cancer1 recruiting

Closed trials

• Completed

  Efficacy and Safety of Inclisiran as Monotherapy in Patients With Primary Hypercholesterolemia Not Receiving Lipid-lowering Therapy.

  NCT05763875· Phase 3· Novartis Pharmaceuticals· Source

• Terminated

  To Assess the Efficacy of the Investigational Products Compared to Placebo in Participants With IPF

  NCT05497284· Phase 2· Novartis Pharmaceuticals· Source

• Recruiting

  A NIS Evaluating Various Injectable and Oral Treatments in Patients With Relapsing Multiple Sclerosis

  NCT05344469· Novartis Pharmaceuticals· Source

  Contact: Novartis Pharmaceuticals

• Completed

  Study of Efficacy, Safety, Tolerability and Quality of Life of Inclisiran (KJX839) vs Placebo, on Top of Ongoing Individually Optimized Lipid-lowering Therapy, in Participants With Hypercholesterolemia

  NCT05192941· Phase 4· Novartis Pharmaceuticals· Source

• Completed

  A Non-interventional Implementation Study to Evaluate Treatment With Inclisiran (Leqvio®) and Other Lipid Lowering Treatments in a Real-world Setting

  NCT05362903· Novartis Pharmaceuticals· Source

• Completed

  Observational Study to Evaluate Fluid Resolution and Effectiveness in Patients Receiving Beovu in Neovascular Age-related Macular Degeneration and Visual Impairment Due to Diabetic Macular Edema

  NCT04543331· Novartis Pharmaceuticals· Source

• Completed

  Extension Study to Assess Effects of Non-interrupted Versus Interrupted and Long Term Treatment of Two Dose Regimes of Secukinumab in Subjects With Hidradenitis Suppurativa

  NCT04179175· Phase 3· Novartis Pharmaceuticals· Source

• Completed

  Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD

  NCT04023552· Phase 3· Novartis Pharmaceuticals· Source

• Completed

  A Non-interventional Study for Women With HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer to Evaluate the Real-world Effectiveness of Treatment Algorithms Beginning With Ribociclib + AI/FUL, or With Endocrine Therapy or Chemotherapy as First Line Treatment

  NCT06311383· Novartis Pharmaceuticals· Source